Zacks Investment Research Downgrades Synthetic Biologics (SYN) to Sell

Zacks Investment Research downgraded shares of Synthetic Biologics (NYSEAMERICAN:SYN) from a hold rating to a sell rating in a research note published on Friday.

According to Zacks, “Synthetic Biologics, Inc. is a biotechnology company focused on the development of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses. The Company is engaged in developing product candidates to treat pulmonary arterial hypertension, relapses in multiple sclerosis, cognitive dysfunction in multiple sclerosis, fibromyalgia and amyotrophic lateral sclerosis. Synthetic Biologics, Inc., formerly known as Adeona Pharmaceuticals, Inc., is headquartered in Ann Arbor, Michigan. “

Separately, HC Wainwright reiterated a buy rating and issued a $6.00 price objective on shares of Synthetic Biologics in a report on Tuesday, November 20th.

NYSEAMERICAN SYN opened at $0.77 on Friday. Synthetic Biologics has a 12 month low of $0.51 and a 12 month high of $14.35.

Synthetic Biologics Company Profile

Synthetic Biologics, Inc, a late-stage clinical company, develops therapeutics designed to preserve the microbiome to protect and restore the health of patients. Its lead product candidates are in Phase III development, such as SYN-004 that is designed to protect the gut microbiome from the effects of commonly used intravenous (IV) beta-lactam antibiotics for the prevention of C.

Further Reading: Stop Order Uses For Individual Investors

Get a free copy of the Zacks research report on Synthetic Biologics (SYN)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Synthetic Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthetic Biologics and related companies with's FREE daily email newsletter.